https://www.pharmnovo.com/post/67-msek-in-new-funding

67 MSEK IN NEW FUNDING

June 3, 2022

We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.

Per von Mentzer, CEO, comments:

"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."

 

Göran Lerenius, Chairman of the board, comments:

"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."

More information:

Press release

LinkedIn

Latest news

View all
June 3, 2022

67 MSEK IN NEW FUNDING

We are pleased to announce that we have raised 67 MSEK in a new share issue led by Sciety.

May 30, 2022

THE CTA IS SUBMITTED

The Clinical Trial Application (CTA) has been submitted to the MPA

November 18, 2021

CTC AWARDED AS CRO

It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)

October 29, 2021

CANADA PATENT GRANT

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.

← Back
No items found.
June 3, 2022

67 MSEK IN NEW FUNDING

We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.

Per von Mentzer, CEO, comments:

"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."

 

Göran Lerenius, Chairman of the board, comments:

"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."

More information:

Press release

LinkedIn

June 3, 2022

67 MSEK IN NEW FUNDING

We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.

Per von Mentzer, CEO, comments:

"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."

 

Göran Lerenius, Chairman of the board, comments:

"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."

More information:

Press release

LinkedIn

Author:

Petra Larson

Author:

Petra Larson

THE CTA IS SUBMITTED

The Clinical Trial Application (CTA) has been submitted to the MPA

Read more →

CTC AWARDED AS CRO

It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)

Read more →

CANADA PATENT GRANT

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.

Read more →

MEET OUR CMO

PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer. Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies.

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map